錦欣生殖(01951.HK):看好業務前景發展 擬回購不超2.381億股
格隆匯3月31日丨錦欣生殖(01951.HK)發佈公告,根據購回授權,公司獲准購回最多238,081,580股股份,佔不多於緊隨在主板上市完成後已發行股份總數的10%。
董事會認為,股份的當前成交價格並未反映其內在價值及實際的業務前景,併為公司購回股份的良機。此外,公司財務狀況維持穩健水平。
因此,由於建議股份購回及其後註銷購回股份可提高股份價值,藉以提升公司股東的回報,故董事會擬根據購回授權行使其權力適時於公開市場購回股份。此外,建議股份購回反映公司對自身價值的認可及行業長遠前景的信心。鑑於以上所述,董事會認為建議股份購回符合公司及其股東的整體利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.